About Vitargus® for Vitreoretinal Vitrectomy
Product Overview
The Global Retinal Detachment Disorder Market Size was valued at USD 1.7 billion in 2021 with millions of patients receiving eye surgery for retinal detachment and vitreous hemorrhage using current vitreous substitutes according to a research report published by Spherical Insights & Consulting.
Vitargus is the first biodegradable vitreous substitute to facilitate retinal reattachment surgery. The optical properties of Vitargus® allowed the patients to see well and facilitated visualization of the fundus immediately following surgery.
ABVC is looking to bring this product to the market in Asia and Europe before seeking FDA approval to bring it stateside.
INDICATED USE
- Retinal Detachment
- Vitreous Hemorrhage
KEY INGREDIENT
- Hyaluronic Acid-Derived Hydrogel
DEVELOPMENT PARTNER
- Major clinical sites in Australia and Thailand
DEVELOPMENT STATUS
- ABVC expects to complete Phase II trial of Vitargus in Thailand, and Australia by the end of 2023.
PATENT STATUS
- Patents granted in Taiwan, USA, Australia, Korea, Canada, EU, Japan, China & Hong Kong. Proprietary market exclusivity to 2031
CLINICAL TRIAL
- First-in-Human (FIH) study was completed for the treatment of 10 patients with Clinical Study Report (CSR) in finalization in 2018, justifying a larger trial for Vitargus®
- Phase II trial of Vitargus® in Thailand and Australia is initiated in Q1 2023
TOXICOLOGY
- No evidence of treatment-related toxicity was observed
SAFETY
- First-in-Human feasibility study successfully completed in 2018
Vitargus® – Vitrectomy Surgery Assistance
Vitargus® Development Timeline
DISCLAIMER: Clinical trials may be in early stages. There is no guarantee that any specific outcome will be achieved. Investments may be speculative, illiquid and there is a risk of loss. Past performance is not indicative of future results.